MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
-$575M
Loss before income
taxes
-$571M
(provision for) benefit
from income taxes
$4M
Interest income
$25M
Other income
(expense)
$1M
Product
$369M
Royalty
$304M
Loss from operations
-$535M
Non-cash interest
expense on liabilities...
$62M
Total revenues
$673M
Total operating
expenses
$1,208M
Research and development
$750M
Selling, general and
administrative
$349M
Cost of sales
$109M
Back
Back
Income Statement
source: myfinsight.com
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)